CMMB: Chemomab Therapeutics Forvard P/E multiplikatori

chemomab.com (CMMB) grafik logotipi

Chemomab Therapeutics (CMMB) eksklyuziv patentlar orqali o'pka va jigar fibroz patologiyalari uchun maqsadli terapiya tizimini ishlab chiqmoqda. Kompaniya suv iste'molini optimallashtirish va ishlab chiqarishning uglerod izini kamaytirish orqali ESG standartlarini joriy etmoqda. Kompaniyaning forward P/E koeffitsiyenti biznesning baholanish tendentsiyasini aks ettiradi va joriy daraja 0.00 atrofida shakllangan. Biroq, ishlab chiqilayotgan dori vositalari portfelida yagona preparatga yuqori bog'liqlik model uchun sezilarli xavflarni yuzaga keltirmoqda.

Chemomab Therapeutics - CMMB Narxning kutilayotgan foydaga nisbati (davr: 04.07.2022 - 16.11.2026)

Chemomab Therapeutics Ltd. (CMMB) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
Fundamental baholash:CMMB Chemomab Therapeutics Ltd
chemomab.com brendining mahsuloti

Noyob fibrozlar terapiyasi uchun maxsus antitanalarning ishlab chiqilishi Chemomab Therapeutics (CMMB) kompaniyasiga yuqori texnologik nishlarda raqobatni minimallashtirish imkonini beradi. Kompaniyaning forward P/E koeffitsiyentini tahlil qilish orqali investor joriy bozor kapitalizatsiyasi va kutilayotgan sof foyda o'rtasidagi bog'liqlikni baholaydi, bu esa operatsion xarajatlarning oshishi kelajakdagi daromadlilikka ta'sirini ochib beradi va bozor siklining bosqichiga qarab aktivning adolatli qiymatini belgilaydi.

Chemomab Therapeutics raqobatchilari tahlili

Kelajakdagi narxning foydaga nisbati Vertex Pharmaceuticals Inc. (VRTX)|Kelajakdagi narxning foydaga nisbati ALNY (Alnylam Inc.)|Forvard P/E multiplikatori INSM (insmed.com)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati United Therapeutics Corporation (UTHR)|BMRN: Prognoz qilingan narxning foydaga nisbati|Narxning kutilayotgan foydaga nisbati BBIO|BGM: Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Cogent Bio (COGT)|XERS (Xeris Biopharma Holdings) - Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati KROS (Keros Therapeutics, Inc.)|Prognoz qilingan narxning foydaga nisbati ARCT (Arcturus Therapeutics Holdings Inc.)|ETON (Eton Pharmaceuticals Inc) - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Kamada KMDA|FULC (Fulcrum Tx) - Narxning kutilayotgan foydaga nisbati|Abeona Therapeutics Inc. - Forvard P/E multiplikatori|Kelajakdagi narx-foyda multiplikatori MREO (mereobiopharma.com)|Protalix BioTherapeutics, Inc. (PLX) - Kelajakdagi narxning foydaga nisbati|Pliant Rx (PLRX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Applied Therapeutics, Inc.|RNTX: Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Gelteq Ltd (GELS)|Prognoz qilingan narxning foydaga nisbati Aytu BioPharma AYTU|Forvard P/E multiplikatori SRXH (SRx Health Solutions Inc)|Forvard P/E multiplikatori Polyrizon Ltd PLRZ|Aeterna Zentaris - Forvard P/E multiplikatori|Cyclo Therapeutics (CYTH) - Prognoz qilingan narxning foydaga nisbati|Inozyme Pharma, Inc. (INZY) - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati reneopharma.com (RPHM)|Kelajakdagi narxning foydaga nisbati COSCIENS Biopharma Inc